Study guide

1.7 Referral Triage, Case Preparation & Records Review

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.7 Referral Triage, Case Preparation & Records Review

Key Takeaways Explain This Topic AI

Domain 1A asks two separate questions about every referral: is genetics the right service (appropriateness), and how fast must it happen (urgency)?

Time-critical genetics referrals are driven by hard external deadlines — gestational age limits, a scheduled surgery or therapy start, a critically ill neonate, or a dying relative who is the only informative person to test.

Reported family history is unreliable: confirm key diagnoses with pathology reports, prior lab reports, and death certificates rather than accepting "she had female cancer."

Ask for the actual laboratory report, not a summary — panel content, methodology, del/dup coverage, and classification date determine whether prior testing is informative or must be repeated.

Case preparation is scored work: identify the informative person to test, confirm sample availability, arrange a qualified interpreter, and confirm who should attend before the session starts.

Last updated: August 2026

1.7 Referral Triage, Case Preparation & Records Review

Quick Answer: Triage answers two independent questions — appropriateness (is genetics the right service for this question?) and urgency (what external deadline is running?). Then prepare: pull pathology and prior lab reports , verify reported diagnoses with documentation, identify the most informative person to test , confirm sample availability , and arrange interpreter/attendance logistics before the visit.

Domain 1A allocates 13 scored items across medical history, teratogen exposure, differential diagnosis or indication, and appropriateness and urgency of referral . Two of ABGC's 37 task statements sit squarely here: assess case urgency, appropriateness, and logistics , and evaluate medical records and elicit additional pertinent information . Board stems phrase this as "what is the most appropriate next step?" before a single risk figure is calculated.

Appropriateness: is this a genetics question?

A referral is appropriate when a genetic evaluation could change a diagnosis, a risk estimate, a management plan, or a reproductive decision. It is inappropriate — or belongs elsewhere first — when the question is not genetic, when a prerequisite workup has not happened, or when another specialty owns the decision.

Referral Appropriate for genetics? Best next step

Two first-degree relatives with early-onset colorectal cancer Yes Schedule; request pathology and any tumor MMR/MSI results first

Adult wants ancestry information only No Redirect; explain the difference between clinical and recreational testing

Child with global developmental delay, no prior workup Yes Schedule; genetics commonly initiates the CMA/exome pathway

Pregnant patient with a screen-positive NIPT Yes, urgent Confirm gestational age and screen result before triaging the slot

  • Patient wants a paternity determination No Redirect to appropriate legal/identity testing channels
  • Employer requests testing of an employee No Decline; this raises GINA Title II and consent problems

Relative of a known pathogenic variant carrier Yes Obtain the familial variant report before scheduling targeted testing

Trap: treating "the referring physician sent them" as sufficient. If the referral question is unclear, the correct action is to contact the referring clinician and clarify the indication — not to spend a 60-minute slot reconstructing why the patient is there.

Urgency: what deadline is actually running?

Urgency in genetics is almost never about symptom severity. It is about an external clock that closes.

Tier Example indications What the clock is

Emergent (hours–days) Critically ill neonate or infant in the NICU/PICU where rapid exome or genome could change management; suspected inborn error of metabolism with decompensation Clinical deterioration; rapid sequencing turnaround only helps if ordered now

Urgent (days–2 weeks) Screen-positive NIPT or anomalous ultrasound; abnormal newborn screen; germline result needed before risk-reducing surgery or before starting a PARP inhibitor; a terminally ill relative who is the only affected person available to test Gestational-age limits on CVS/amniocentesis and on pregnancy options; a scheduled operation; a therapy decision; a dying informative relative

Routine (weeks) Asymptomatic cascade testing for a known familial variant; preconception carrier screening with no pregnancy; hereditary cancer risk assessment without pending surgery No fixed deadline; standard scheduling

Deferrable Predictive testing where the client is ambivalent or in acute crisis Psychosocial readiness, not logistics — deferral here is a clinical decision, not a triage decision

The deceased or dying relative problem

The single most time-sensitive non-pregnancy scenario on the exam is an affected relative in hospice. Testing the affected person is far more informative than testing an unaffected relative, and once that person dies the opportunity usually closes. Appropriate urgent action includes contacting the relative's team about sample collection, discussing banking DNA even if testing is not performed now, and asking whether stored pathology blocks or a newborn screening card exist. Do not defer this to a routine slot four months out.

Records review: what to obtain and why

Reported history is a hypothesis; documentation is evidence. Studies of family-history accuracy consistently find that reports of common cancers are frequently wrong in site, laterality, or age.

Record What it settles

Pathology reports Actual tumor site and histology — "ovarian cancer" is often cervical, uterine, or metastatic; triple-negative breast pathology changes the differential

Prior genetic test reports (the full PDF) Which genes were analyzed, methodology, whether deletion/duplication analysis was included, the classification and its date

  • Newborn screening results Whether a metabolic condition was already excluded, and by which analyte
  • Imaging and echocardiograms Aortic root measurements, structural anomalies, skeletal survey findings
  • Autopsy and fetal pathology The only source of phenotype for a prior pregnancy loss
  • Obstetric records Gestational dating, exposures, prior pregnancy outcomes
  • Death certificates Confirmation of cause and age at death when medical records are unavailable
  • Reading a prior test report critically

"She was tested and it was negative" is not usable information. Ask four questions of every prior report:

What was on the panel? A 2014 two-gene BRCA1/2 test does not exclude PALB2 , ATM , or Lynch genes.

What method? Sequencing without del/dup analysis misses large rearrangements; a targeted familial-variant test excludes only that variant.

When was it classified? A VUS from 2016 may now be pathogenic or benign — reclassification is the reason recontact policy exists.

Who was tested? A negative result in an unaffected relative is far less informative than a negative in the affected proband — this is uninformative-negative territory, not reassurance.

Logistics that belong in the triage note

Who should attend. A pediatric session may need both parents; a cascade session may usefully include the sibling; a predictive-testing session may deliberately exclude a coercive partner.

Language access. Identify interpreter need at triage, not at the door. A qualified medical interpreter must be scheduled in advance; family members are not an acceptable substitute for consent conversations.

Modality. Telegenetics may shorten the wait for a routine cascade case but is inappropriate when a physical examination or dysmorphology assessment drives the differential.

Sample and specimen access. Confirm whether the informative relative is testable, whether stored tissue exists, and whether consent or next-of-kin authorization is needed.

Coverage groundwork. Flag prior-authorization requirements at triage so the appointment is not wasted discovering them.

Common triage traps

Booking a routine slot for a pregnant patient at 22 weeks whose diagnostic options are closing.

Accepting "family history of cancer" without pathology, then building a pedigree and a risk model on the wrong tumor.

Testing the unaffected worried relative because they are the one who called, when an affected relative is available and willing.

Assuming a prior negative result is comprehensive without reading the report.

Discovering at the visit that no interpreter was arranged, and proceeding anyway with a family member interpreting a consent discussion.

Treating urgency and appropriateness as the same judgment — an urgent-sounding referral can still be the wrong service, and a calm-sounding one can be on a two-week clock.